Down 13.64%: 9G2.SI Singapore Inst. of Adv. Medicine (SES) Jan 2026: 0.08 SGD
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2.SI stock) fell 13.64% to S$0.057 as the SES session closed on 16 Jan 2026. Trading showed heavy participation with 9,129,900 shares changing hands, about 2.02x average volume. The move put the counter below its 50-day average S$0.06312 while still above the 200-day S$0.03999, signalling short-term weakness inside a multi-month recovery. We review drivers, valuation, technicals and Meyka AI model forecasts for near-term price targets and risk points
9G2.SI stock: Market action and top loser move
9G2.SI stock led local small-cap losers on 16 Jan 2026, dropping 13.64% from the previous close of S$0.066 to S$0.057. Volume spiked to 9,129,900 versus an average of 5,064,111, confirming distribution. The intraday range was S$0.055–S$0.060, and the stock now sits nearer its year low S$0.026 than its year high S$0.089, highlighting elevated volatility.
Price drivers and 9G2.SI stock news
There is no company earnings announcement scheduled, and public headlines are limited; sector peers are mixed in January. Market participants pointed to profit-taking after recent gains and thin liquidity in the Medical – Care Facilities group. For peer comparisons and listings context see the market note source.
Financials and valuation snapshot for 9G2.SI stock
The company reports EPS -0.03 and a reported PE around -1.97, reflecting trailing losses. Key ratios: PB 1.13, debt to equity 1.05, current ratio 0.31, and market cap S$61,789,823. Revenue per share is S$0.01 and book value per share is S$0.05239, signalling a thin equity cushion relative to outstanding shares 1,047,285,133.
Technical and trading signals for 9G2.SI stock
Technicals show mixed momentum: RSI 56.97 and ADX 46.97 indicating a strong trend context but MFI 80.72 suggests short-term overbought pressure prior to the sell-off. Price sits below the 50-day moving average S$0.06312 and above the 200-day S$0.03999, while OBV remains elevated. Traders should watch daily support S$0.055 and initial resistance S$0.060.
Meyka AI grade and model forecast for 9G2.SI stock
Meyka AI rates 9G2.SI with a score out of 100: 57.04 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly S$0.06, quarterly S$0.08, and yearly S$0.08005. Versus the current price S$0.057, that implies upside of 5.26% (monthly) and 40.45% (yearly). Forecasts are model-based projections and not guarantees.
Risks and catalysts for 9G2.SI stock outlook
Principal risks include continued losses (negative EPS), tight liquidity, weak current ratio 0.31, and a debt load with debt/equity 1.05. Catalysts that could reverse the down leg are a company earnings beat, higher-margin service contracts, or clearer debt reduction plans. Monitor corporate updates, sector demand in Healthcare, and volume spikes for confirmed trend changes.
Final Thoughts
9G2.SI stock closed the SES session on 16 Jan 2026 at S$0.057, down 13.64% on heavy volume. Fundamentals show a loss-making profile with EPS -0.03, negative profitability margins, and a thin current ratio 0.31, which raises short-term financial risk. Technicals point to a trend in play but overbought indicators and high relative volume suggest recent moves are reactive. Meyka AI’s model flags a near-term target of S$0.06 and a 12-month projection S$0.08005, implying roughly 40.45% upside from today’s price; a three-year projection at S$0.13933 implies larger long-term upside but with materially higher uncertainty. Investors should treat the Meyka grade C+ (HOLD) and forecasts as data points for portfolio sizing rather than buy/sell signals. For active traders, watch S$0.055 support and a break above S$0.063 for short-covering signs. For longer-term investors, demand visibility and cashflow improvement remain prerequisites before upgrading exposure. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are not guarantees.
FAQs
What drove the 13.64% fall in 9G2.SI stock?
The drop on 16 Jan 2026 reflected heavy volume 9,129,900, profit-taking after recent gains and limited company news. Thin liquidity in the Medical – Care Facilities sector amplified the move.
What is Meyka AI’s price forecast for 9G2.SI stock?
Meyka AI’s model projects S$0.06 monthly and S$0.08005 in 12 months, implying roughly 40.45% upside versus the current S$0.057. Forecasts are model-based and not guarantees.
How does valuation look for 9G2.SI stock?
Valuation shows EPS -0.03, PE roughly -1.97, PB 1.13, and enterprise concerns from a low current ratio 0.31. These metrics reflect a loss-making small-cap with balance sheet constraints.
What short-term levels should traders watch for 9G2.SI stock?
Traders should watch immediate support at S$0.055 and resistance at S$0.060–S$0.063. A sustained break above S$0.06312 (50-day MA) would lessen short-term downside risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
